RARE
Ultragenyx
NASDAQ: RARE · HEALTHCARE · BIOTECHNOLOGY
$26.30
-6.01% today
Updated 2026-06-05
Market cap
$2.40B
P/E ratio
—
P/S ratio
3.58x
EPS (TTM)
$-6.10
Dividend yield
—
52W range
$18 – $42
Volume
1.7M
Ultragenyx (RARE) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$26.30
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.4B | $0.4B | $0.4B | $0.6B | $0.7B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -90.90%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.